The AD-Index, which tracks imbalances in MAP Kinase Erk1/2 phosphorylation, has emerged as a highly sensitive and specific biomarker for distinguishing AD patients from healthy controls and those with other forms of dementia [23]. Here, MAPK3 is linked to Alzheimer disease.